BORDERNETwork Training on P ost- E xposure- P rophylaxis Dr.
med. Wolfgang Gthoff / Alexander Leffers, M.A. www.bordernet.eu
www.aidshilfe-potsdam.de
Folie 2
This presentation arises from the BORDERNETwork project which
has received funding from the European Union, in the framework of
the Health Program, and co- funding of the Ministry of Environment,
Health and Consumer Protection of the Federal State of Brandenburg.
The sole responsibility of any use that may be made of the
information lies with the authors (SPI, AIDS-Hilfe Potsdam
e.V.)
Folie 3
Table of Contents Transmission Conditions for PEP Guidelines on
PEP Blood Control Problems with PEP
Folie 4
PEP HIV - Exposure When? Injury with HIV contaminated
instruments Wetting of open wounds and mucosa with HIV contaminated
fluids Unprotected sex with an HIV infected person Use of HIV
contaminated needles (needle sharing) Transfusion of HIV
contaminated blood or blood products Postexpositionelle Prophylaxe
der HIV-Infektion. Gemeinsame Empfehlung der Deutschen
AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS-
Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S
16-S 33.
Folie 5
PEP - Guidelines The ultimate goal of PEP is: to suppress any
viral replication that may occur, to shift the biological advantage
to the host cellular immune system to prevent or abort early
infection http://www.who.int/hiv/pub/guidelines/PEP/en/
http://www.hivguidelines.org/wp-
content/uploads/2009/05/pep_card.pdf
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.ht m
Folie 6
Occupational PEP Probability of Transmission Factors
influencing transmission: Kind of transmitting material (Viral
concentration is highest in the blood) Kind of exposure: Hollow
needle Cut injury Open wound Exposure of mucosa Viral concentration
from index person Postexpositionelle Prophylaxe der HIV-Infektion.
Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V.
und der sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch
Med. Wochenschr 2009; 134: S 16-S 33.
Folie 7
Average risk: Percutaneous 0.3% Mucous membrane 0.1% Non-intact
skin
PEP when to start and time limits Entry and Fusion2h
DNA-Integration in nucleus12h Viral replication after another12h
PEP within 24h (best - start within first 2h) >72h after
Exposition: PEP is not practical Replication of HIV and Targets of
Therapy Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame
Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der
sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med.
Wochenschr 2009; 134: S 16-S 33.
Folie 16
Medications for PEP (German Austrian Guidelines) Tenofovir
300mg plus Emtricitabin 200mg as combination product (Truvada 1x1
pill) combined with Kaletra (Lopinavir + Ritonavir) 2 x 400/100mg
or Sustiva 1 x 600mg Alternative: Combivir 2 x 1 pill (Zidovudin +
Lamivudin) Alternative: Invirase (2 x 1000mg plus Ritonavir 2 x
100mg) or Fosamprenavir Indinavir Postexpositionelle Prophylaxe der
HIV-Infektion. Gemeinsame Empfehlung der Deutschen
AIDS-Gesellschaft (DAIG e.V. und der sterreichischen AIDS-
Gesellschaft (AG) et al., in: Dtsch Med. Wochenschr 2009; 134: S
16-S 33.
Folie 17
European Guidelines HIV- rapid test from Index person If Index
persons HIV-RNA > 1000 copies/ml testing of drug resistance
Start PEP if possible within 4h and not later then 48h Duration: 4
weeks Medication: Truvada (TDF/FTC) 1 x 1 pill Alternative:
Combivir (ZDV/3TC)2 x 1 pill + Kaletra (LPVr) 2 x 2 pills
Alternative: Invirase 500(SQV) 2 x2 capsules and Norvir (RTV) 2 x
100mg Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame
Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der
sterreichischen AIDS- Gesellschaft (AG) et al., in: Dtsch Med.
Wochenschr 2009; 134: S 16-S 33.
Folie 18
Blood Controls Serologic control (HIV, possible HBV, HCV): at
the start after 6 weeks, after 3 month after 6 month Laboratory
tests: at the start, after 2 weeks and after 4 weeks: Blood count,
liver enzymes, kidney function, blood sugar, urine
Folie 19
Problems regarding HIV PEP Pregnancy and lactation period No
substance is harmless! PEP only at high risk Experience only with
Retrovir and Epivir Sustiva (Efavirenz) is contraindicated!
Folie 20
Period between exposition and starting PEP not longer than 24 h
Problems regarding HIV PEP
Folie 21
High risk through massive inoculation of infections
material
Folie 22
Problems regarding HIV PEP Strong side effects of HAART (mental
Efavirenz)
Folie 23
Problems regarding HIV PEP Index person gets HAART and drug
resistance is probable Course of CD4 cells Opportunistic infections
(OI)
Folie 24
HIV-Infection known? How fast is an HIV-test possible? HIV-
rapid tests every time for every physician available? PEP - Index
person
Folie 25
Treatment Algorithm Did an exposure to a potentially
HIV-infected fluid occur? Did a significant risk of transmission of
HIV occur? (Contact of a HIV negative person with an HIV positive
person (index person/source patient) Is the patient presenting
within ideally 2 hours, not later than 72 hours of the exposure?
Can the source patient be interviewed? Initiation of PEP regimen:
PEP within 24h (best - start within first 2h) HIV monitoring YES NO
No indication of PEP No follow-up needed No indication of PEP No
follow-up needed PEP not indicated Follow-up HIV testing Adopted
from: New York State Department of Health/ AIDS Institute:
Recommendations for HIV Postexposure Prophylaxis (PEP) URL:
http://www.hivguidelines.org/wp-content/uploads/2009/05/pep_card.pdf
Adopted from: Postexpositionelle Prophylaxe der HIV-Infektion.
Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V.)
und der sterreichischen AIDS-Gesellschaft (AG) et al. in: Dtsch
Med. Wochenschr 2009; 134: S 16-S 33. If yes: interview on HIV
status or infection risk, resp. test/rapid test on HIV If no:
belongs the source patient to a high risk group (with high
prevalence) If yes: Individual benefit-risk assessment If no: PEP
not indicated Serological test of source patient is confirmed HIV
negative no evidence of acute retroviral syndrome Serological test
of source patient is confirmed HIV positive Evidence of acute
retroviral syndrome occurs Source patient is unknown, unwilling
etc. Stop PEPContinue PEP for 4 weeks